Internal Med Medical News about Tourette Syndrome Cannabinoids

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

5. Rapid correction of low vitamin D status in nursing home residents

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Cannabinoids for Tourette's Syndrome
Cochrane Reviews, 10/22/09

Curtis A et al. – Only two trials were found that met the inclusion criteria. Both compared a cannabinoid, delta–9–Tetrahydrocannabinol (delta9THC), either as monotherapy or as adjuvant therapy, with placebo. One was a double blind, single dose crossover trial and the other was a double blind, parallel group study. A total of 28 different patients were studied. Although both trials reported a positive effect from delta9THC, the improvements in tic frequency and severity were small and were only detected by some of the outcome measures. Not enough evidence to support the use of cannabinoids in treating tics and obsessive compulsive behaviour in people with Tourette's syndrome.

<< Previous
Antibiotic therapy for Shigella dysentery

Next >>
Efficacy and safety of pioglitazone/metformin fixed-dose...